Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M

Vera Therapeutics, Inc.

Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
Mean annualized eGFR slope of -0.6 mL/min/1.73m2/year; 90% treatment completion rate.
Phase 3 ORIGIN 3 topline expected Q2 2025; BLA submission planned H2 2025; commercial launch target 2026.
Preliminary unaudited cash, cash equivalents and marketable securities ~$353.2M as of Sep 30, 2024.
Data simultaneously published in Journal of the American Society of Nephrology; presented at ASN Kidney Week.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.